Status:
RECRUITING
A Retrospective Study: Evaluation of the Efficacy of Immunotherapy With Rare Mutations in Non-small Cell Lung Cancer
Lead Sponsor:
Yongchang Zhang
Collaborating Sponsors:
Hunan Province Tumor Hospital
Conditions:
Non Small Cell Lung Cancer
Eligibility:
All Genders
18-75 years
Brief Summary
In advanced non-small cell lung cancer, there will be some rare mutations, such as ALK, KRAS, etc. The efficacy of these immunotherapies on these different rare mutations has not been reported. Theref...
Eligibility Criteria
Inclusion
- Diagnosed as advanced non-small cell lung cancer
- Confirmed as KARS, ALK, ERBB2, MET, RET, BRAF mutation
Exclusion
- The patient is diagnosed with small cell lung cancer
Key Trial Info
Start Date :
January 1 2023
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
January 12 2025
Estimated Enrollment :
186 Patients enrolled
Trial Details
Trial ID
NCT04777175
Start Date
January 1 2023
End Date
January 12 2025
Last Update
September 19 2024
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Hunan Cancer Hospital
Changsha, Hunan, China, 410013
2
Hunan Cancer hospital
Changsha, Hunan, China